Tigress Financial's Ivan Feinseth Notes Many Co.'s Working To Produce Coronavirus Vaccines/Treatments; Says If Remdesivir Is Ramped Up, Gilead May Need To Work With Others To License And Produce It, And It May Not Be As Profitable